Ignite Creation Date:
2024-05-06 @ 4:05 PM
Last Modification Date:
2024-10-26 @ 2:03 PM
Study NCT ID:
NCT04862286
Status:
ENROLLING_BY_INVITATION
Last Update Posted:
2024-06-17
First Post:
2021-04-26
Brief Title:
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous SC Injection of Risankizumab Who Have Completed Participation in Study M19-977
Sponsor:
AbbVie
Organization:
AbbVie